Thermo Fisher Scientific Inc. Company Analysis & Research
Thermo Fisher Scientific is the world leader in serving science with annual revenue over $40 billion. The company serves customers accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, improving patient health through diagnostics, and developing life-changing therapies.
The company delivers innovative technologies, purchasing convenience, and pharmaceutical services through industry-leading brands including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Its scale, recurring revenue base, deep customer integration, and disciplined capital allocation create durable competitive advantages with consistent free cash flow generation.
Company Overview
Founded: 2006. Headquarters: Waltham, Massachusetts, US. Revenue: $44.56B. Employees: ~40,000. Market Cap: $640B+. Ticker: TMO (NYSE).
Industry
Life Sciences, Scientific Instruments & Lab Equipment, Diagnostics & Contract Research
Cyborg Score: 8/10 — Strong
Market-leading life sciences company with solid financials, strategic acquisitions, and consistent innovation positioning it for sustainable growth.
Full year 2025 revenue grew 4% to $44.56 billion with strong earnings growth. The balance sheet is solid with a current ratio of 1.5 and debt-to-equity ratio of 0.7. Recent strategic acquisitions of Clario Holdings ($8.75B) and Solventum's Purification & Filtration business ($4.0B) strengthen market position.
Key Strategic Insights for Thermo Fisher Scientific Inc.
- FY2026 revenue guidance of $46.3-$47.2 billion aligns with market expectations.
- Company embedding AI capabilities and OpenAI integration into products to enhance productivity and support innovation in precision medicine.
- Q4 2025 beat Wall Street estimates driven by strong demand for tools and services used in drug development.
- 19 analyst average rating is "Strong Buy" with 12-month target of $639.83 (26.74% upside).
Recent Developments
- (January 2026) Q4 2025 revenue grew 7% to $12.21B; full year revenue reached $44.56B with 4% growth
- (October 2025) Announced acquisition of Clario Holdings for $8.75B to enhance clinical trial solutions
- (September 2025) Completed $4.0B acquisition of Solventum's Purification & Filtration business
- (2025) Strategic collaboration with NVIDIA to power AI-based laboratory solutions
Competitors & Competitive Landscape
- Illumina — Genomics and sequencing instruments
- Agilent Technologies — Analytical instruments and lab solutions
- Mettler-Toledo International — Precision instruments and lab equipment
- PerkinElmer — Diagnostics and life sciences instruments
Key competitors include Illumina, Agilent Technologies, IDEXX Laboratories, Mettler-Toledo International, and Zoetis. Thermo Fisher maintains industry leadership through scale, integrated product portfolios, and recurring revenue from consumables and services that create switching costs for large pharmaceutical and biotech customers.
More Company Research
Steyr Motors AG Wajax Corporation Italtile Limited Peoples Bancorp Inc. National Industrialization Company Helios Towers plc Plus500 Ltd. Plains GP Holdings, L.P. JFrog Ltd. South32 Limited Southwest Airlines Co. London Stock Exchange Group plc Superior Industries International, Inc. The ONE Group Hospitality, Inc. Scott Technology LimitedFull Company Research Reports
Looking for a more in-depth analysis of Thermo Fisher Scientific Inc.? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.